ClinicalTrials.gg
CompletedNCT00674232Updated May 7, 2008

Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment

An interventional study of 600 mcg misoprostol and Surgical treatment in Incomplete Abortion, sponsored by Gynuity Health Projects. Completed at 3 sites in 2 countries. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-05-07.

Sponsored by Gynuity Health Projects · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
14 Years and older
Sex
Female
01

Study summary

This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.

02

Conditions studied

  • Incomplete Abortion

Browse trials for

Keywords

  • incomplete abortion
  • spontaneous miscarriage
03

In context

Abortion, Incomplete

24 studies on the registry are indexed under Abortion, Incomplete; 5 are open to participants now.

This study's enrollment of 311 is close to the median of 311 across 21 interventional studies indexed under Abortion, Incomplete.

Browse Abortion, Incomplete studies →

Lead sponsor

Gynuity Health Projects is the lead sponsor of 113 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • past or present history of vaginal bleeding during pregnancy
  • open cervical os
  • evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound)
  • surgical evacuation of the uterus would be advised as course of action if misoprostol was not available
  • generally in good health
  • woman lives or works within one hour of study site
  • woman willing to provide contact information for follow up purposes
  • given

Exclusion criteria

Exclusion Criteria:

  • to study drug
  • uterine size larger than 12 weeks LMP
  • signs of severe infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Misoprostol

    Group 1 randomized to take single dose of 600 mcg oral misoprostol

    Drug: 600 mcg misoprostol

  • Other
    Surgical treatment

    Group 2 randomized to receive standard surgical treatment as per local protocol (D\&C or MVA)

    Procedure: Surgical treatment

Interventions

  • single dose of misoprostol taken orally

    Also known as: Cytotec

  • ProcedureSurgical treatment

    Either dilation and curettage or manual vacuum aspiration, as per local protocol

    Also known as: D&C, MVA

06

What researchers measure

Primary outcomes

  1. complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reason

    Time frame: one week after initial treatment

Secondary outcomes

  1. side effects

    Time frame: measured at follow up visit one week after initial treatment

  2. acceptability

    Time frame: measured at follow up visit one week after initial treatment

07

Study locations

3 sites
  • Hospital del Dia, CEMOPLAF
    Quito, Ecuador
  • Hospital Gineco-obstetrico Isidro Ayora
    Quito, Ecuador
  • Hospital Maternidad Concepcion Palacios
    Caracas, Venezuela
08

References and documents

Publications

  • Montesinos R, Durocher J, Leon W, Arellano M, Pena M, Pinto E, Winikoff B. Oral misoprostol for the management of incomplete abortion in Ecuador. Int J Gynaecol Obstet. 2011 Nov;115(2):135-9. doi: 10.1016/j.ijgo.2011.06.015. Epub 2011 Aug 26. PubMed 21872244 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2008
First posted
May 7, 2008
Start
May 2006
CompletionActual
Oct 2007
Last update
May 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00674232
First posted
May 7, 2008
Start date
May 2006
Completion
Oct 2007
Last update
May 7, 2008

Study contacts

Melanie Peña, MPH, MA
study director · Gynuity Health Projects
Jill Durocher
study director · Gynuity Health Projects

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Misoprostol

Start the discussion